- Home
- ICON vs ADTX Comparison
ICON vs ADTX Comparison
Compare ICON & ADTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICON
- ADTX
- Stock Information
- Founded
- ICON 2023
- ADTX 2017
- Country
- ICON Greece
- ADTX United States
- Employees
- ICON N/A
- ADTX N/A
- Industry
- ICON
- ADTX Biotechnology: Pharmaceutical Preparations
- Sector
- ICON
- ADTX Health Care
- Exchange
- ICON Nasdaq
- ADTX Nasdaq
- Market Cap
- ICON 4.7M
- ADTX 4.9M
- IPO Year
- ICON 2024
- ADTX 2020
- Fundamental
- Price
- ICON $2.07
- ADTX $0.70
- Analyst Decision
- ICON Strong Buy
- ADTX
- Analyst Count
- ICON 1
- ADTX 0
- Target Price
- ICON $4.50
- ADTX N/A
- AVG Volume (30 Days)
- ICON 34.3K
- ADTX 359.8K
- Earning Date
- ICON 09-10-2025
- ADTX 11-17-2025
- Dividend Yield
- ICON 454.11%
- ADTX N/A
- EPS Growth
- ICON N/A
- ADTX N/A
- EPS
- ICON N/A
- ADTX N/A
- Revenue
- ICON $6,137,000.00
- ADTX $12,051.00
- Revenue This Year
- ICON $94.05
- ADTX $15,768.94
- Revenue Next Year
- ICON $18.81
- ADTX N/A
- P/E Ratio
- ICON N/A
- ADTX N/A
- Revenue Growth
- ICON 25.60
- ADTX N/A
- 52 Week Low
- ICON $1.60
- ADTX $0.66
- 52 Week High
- ICON $130.80
- ADTX $464.98
- Technical
- Relative Strength Index (RSI)
- ICON 44.28
- ADTX 28.04
- Support Level
- ICON $2.00
- ADTX $0.67
- Resistance Level
- ICON $2.11
- ADTX $0.77
- Average True Range (ATR)
- ICON 0.10
- ADTX 0.07
- MACD
- ICON -0.00
- ADTX -0.02
- Stochastic Oscillator
- ICON 14.71
- ADTX 3.19
About ICON Icon Energy Corp. Common stock
Icon Energy Corp is a growth-oriented shipping company providing seaborne transportation services for dry bulk cargoes via its fleet of oceangoing vessels. The company generates its revenues by chartering its vessels to regional and international dry bulk operators, commodity traders and end users.
About ADTX Aditxt Inc.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues.